Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Glioblastoma 2Recurrence 1Meningeal Neoplasms 1Inhibition, Psychological 1Hereditary Sensory and Autonomic Neuropathies 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 23Radiosurgery 21Temozolomide 14Bevacizumab 12pembrolizumab 10Specimen Handling 9Nivolumab 8Radiotherapy 7Ipilimumab 7Magnetic Resonance Imaging 6Cyclophosphamide 5Capecitabine 5Blood Specimen Collection 5encorafenib 4Radiation 4Neuropsychological Tests 4Mental Status and Dementia Tests 4Memantine 4Carboplatin 4fludarabine 3fluciclovine F-18 3binimetinib 3abemaciclib 3Watchful Waiting 3Proton Therapy 3Etoposide 3Dexamethasone 3Adrenal Cortex Hormones 3trastuzumab deruxtecan 2sacituzumab govitecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Brain Neoplasms × AZD1390 × Clear all
NCT03423628 2025-12-22

A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer

AstraZeneca

Phase 1 Recruiting
180 enrolled
CNS

Brain Neoplasms, Glioblastoma, Inhibition, Psychological, Meningeal Neoplasms, Hereditary Sensory and Autonomic Neuropathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡